Health Care Facilities

GZYK

GZYK released FY2026 Q1 earnings on April 27 After-Market (BJT), actual revenue CNY 187.04 M, actual EPS CNY -0.01

GZYK released FY2025 Annual Earnings on April 23 After-Market (BJT), with actual revenue of CNY 885.18 M and EPS of CNY -0.04

GZYK released FY2025 Q4 earnings on April 23 After-Market (BJT), actual revenue CNY 221.69 M, actual EPS CNY -0.0403

GZYK to Release FY2026 Q1 Earnings Report on April 28 After-Market BJT

GZYK to Release FY2025 Earnings on April 24 After-Market (BJT)

GZYK released FY2025 9 Months Earnings on October 23 After-Market (BJT), Actual Revenue CNY 663.49 M, Actual EPS CNY 0

GZYK released FY2025 Q3 earnings on October 23 After-Market (BJT), actual revenue CNY 227.34 M, actual EPS CNY 0

GZYK FY2025 Q3 Earning Release on October 24, 2025 After-Market (BJT)

GZYK released FY2025 Semi-Annual earnings on August 21 Pre-Market (BJT), actual revenue CNY 436.15 M, actual EPS CNY 0

GZYK released FY2025 Q2 earnings on August 21 Pre-Market (BJT), actual revenue CNY 227.99 M, actual EPS CNY 0

GZYK to Release FY2025 Semi-Annual Earnings on August 22, 2025 (BJT)

Guangzheng Eye Hospital Announces 2025 Q1 Financial Report

GZYK released FY2025 Q1 earnings on April 27 After-Market (BJT), actual revenue CNY 208.17 M, actual EPS CNY 0

Guangzheng Ophthalmology Inc. Net Loss of 175 Million in 2024

GZYK released FY2024 Annual Earnings on April 23 After-Market BJT, actual revenue CNY 892.84 M, actual EPS CNY -0.34

GZYK released FY2024 Q4 earnings on April 23 After-Market BJT, actual revenue CNY 194.06 M, actual EPS CNY -0.3113

GZYK FY2025 Q1 Earnings Release on April 28 After-Market BJT

GZYK FY2024 Annual Earnings Release Scheduled for April 24, 2025, After-Market BJT

Guangzheng Ophthalmology Expects Net Profit Loss of 120 Million to 180 Million Yuan in 2024

Guangzheng Eye Hospital increases capital by 40 million yuan to Dongqu Eye Hospital

ZEISS Vision Care has formed a strategic partnership with Medical Eyeglass Center (MEC) to enhance optical care and patient experience. This multi-year agreement designates MEC as the exclusive optical dispensary management organization for ZEISS, providing access to advanced lens innovations and operational support. The collaboration aims to integrate optical dispensaries into clinical care, improving patient satisfaction and driving growth for independent eye care practices. Both companies emphasize a commitment to clinical excellence and operational efficiency, setting a new standard in optical care delivery.

fidelity

Carl Zeiss Meditec AG

ZEISS Vision Care and Medical Eyeglass Center Form Strategic Partnership, Combining Optical Excellence with Patient-Centric Operational Systems

601187

002524

603939

603168

On October 27th, a total of 10 listed companies had their restricted shares unlocked, with a total market value of approximately 18.54 billion yuan. The specific situation of the restricted shares unlocked today is as follows: Stock Abbreviation Stock Code Restricted Share Type Unlocked Shares Xiamen Bank 601187 Extended Restricted Lock-up Period Circulation 1.348 billion GZYK 002524 Equity Incentive Restricted Circulation 2.2245 million SPAS 603168 Equity Incentive Restricted Circulation 30,000 Yifeng Pharmacy 603939 Equity Incentive Restricted Circulation 195,000 Jihong Co., Ltd. 002803 Equity Incentive Restricted Circulation 1.98 million Mingyang Circuit 300739 Equity Incentive Restricted Circulation 1.2387 million Arrow Home 001322 Pre-issue Shares Restricted Circulation 800 million Ruichen Environmental Protection 301273 Pre-issue Shares Restricted Circulation 37.0125 million Jinchengzi 688291 6.9 million Wei Ce Technology 688372 270.328 million

Zhitong

XIAMEN BANK

Yifeng Pharmacy

SPAS

Zhitong A-share lock-up release overview | October 27

According to the Zhitong Finance APP, GZYK released its third-quarter report for 2025. In the first three quarters, the company achieved an operating income of 663 million yuan, a year-on-year decrease of 5.05%. The net profit attributable to shareholders of the listed company was 173,400 yuan, a year-on-year increase of 100.83%. The net loss attributable to shareholders of the listed company, after deducting non-recurring gains and losses, was 9.1753 million yuan

GZYK released its performance for the first three quarters, with a net profit attributable to the parent company of 173,400 yuan, a year-on-year increase of 100.83%

GZYK announced that the revenue for the third quarter was 227 million yuan, an increase of 4.82% year-on-year; the net profit loss was 1.2455 million yuan, a decrease of 94.36%. The revenue for the first three quarters was 663 million yuan, a year-on-year decrease of 5.05%; the net profit was 173,400 yuan, an increase of 100.83% year-on-year

GZYK: Net profit loss of RMB 1.2455 million in the third quarter, a decrease of 94.36%

GZYK announced that its wholly-owned subsidiary Zhongxing Ophthalmology and New Vision Ophthalmology applied for a credit limit of 30 million yuan from the Shanghai Branch of China Merchants Bank, with the company and related parties providing joint liability guarantees. After this guarantee, the total guarantee amount for the company and its subsidiaries reaches 511.09 million yuan, accounting for 453.50% of the most recent audited net assets. This guarantee is an internal mutual guarantee, with no external guarantee risk

GZYK's subsidiary applies for credit, with the cumulative guarantee amount accounting for 453.50% of net assets

003020

301096

688050

301103

Ophthalmology medical concept stocks surged during the session, with SPAS hitting the daily limit, Xingqi Eye Medicine rising over 10%, Lifeon Pharmaceutical previously hitting the daily limit, and Bio-S, Eyebright Medical, GZYK, and HESH also following suit

Lifeon Pharmaceutical

Bio-S

Eyebright Medical

HESH

Ophthalmology medical concept stocks surged, SPAS hit the daily limit in the afternoon

According to the announcement from GZYK, the company plans to transfer all of its equity in Toksun County Xintianshan Gas Co., Ltd. (referred to as "Xintianshan") to its wholly-owned subsidiary GZYK Energy (Bazhou) Co., Ltd. (referred to as "GZYK Bazhou") in order to optimize resource allocation and streamline management structure, thereby enhancing management efficiency and professional management level. After the completion of this equity transfer, Xintianshan will become a subsidiary of GZYK Bazhou

GZYK plans to transfer all equity of Xintianshan to its subsidiary GZYK Bazhou

According to the Zhitong Finance APP, GZYK disclosed its first-quarter report for 2025, showing that the company achieved revenue of 208 million yuan, a year-on-year increase of 4.32%; the net profit attributable to the parent company was 570,000 yuan, turning from a loss to a profit year-on-year; the net profit excluding non-recurring gains and losses was a loss of 1.59 million yuan, narrowing year-on-year. The basic earnings per share was 0 yuan

GZYK released its first-quarter performance, with a net profit attributable to the parent company of 570,000 yuan, turning a profit from a loss year-on-year

GZYK announced that the operating revenue for 2024 is 893 million yuan, a year-on-year decrease of 16.94%. The net loss attributable to shareholders of the listed company is 175 million yuan, compared to a net profit of 9.255 million yuan in the same period last year. The basic earnings per share are -0.34 yuan/share. The company plans not to distribute cash dividends, not to issue bonus shares, and not to increase capital using reserves

GZYK: Net loss of 175 million yuan in 2024

603716

Today, the three major A-share indices fell slightly, but AI medical concept stocks rose against the trend, boosted by the news of Huawei forming a medical and health team. Thalys, RunDa Medical, and GZYK hit the daily limit. The application of AI in the medical field is rapidly expanding, driving a reevaluation of industry value. Industry insiders believe that Huawei's advantages in the AI field will support the development of the medical industry. CITIC Securities pointed out that the AI pharmaceutical sector is undergoing rapid transformation, with algorithm updates and computing power support laying the foundation for its application

hkcd.com

Thalys

Stock Market Barometer | It is rumored that Huawei has officially formed a medical and health team, AI medical concept stocks continue to welcome good news, many stocks hit the daily limit

GZYK(002524.SZ)